Capricor Therapeutics' Strategic Public Offering and Stock Performance

Capricor Therapeutics (NASDAQ:CAPR) is conducting a public offering of common stock to fund the advancement of its product candidates, including Deramiocel for DMD.Analysts from Maxim Group and H.C. Wainwright have set optimistic price targets for CAPR, suggesting a potential increase of approximately 98.56% and 99.65%, respectively.The company's stock has shown volatility but maintains a strong market capitalization of approximately $1.23 billion, indicating significant investor interest.Capricor Therapeut ...